{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:52:45Z","timestamp":1782478365445,"version":"3.54.5"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T00:00:00Z","timestamp":1746921600000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Key Clinical Specialty Scientific Research Project","award":["Z2023098"],"award-info":[{"award-number":["Z2023098"]}]},{"name":"Hunan Provincial Health High-Level Talent Scientific Research Project","award":["R2023125"],"award-info":[{"award-number":["R2023125"]}]},{"name":"Hunan Cancer Hospital Climb Plan","award":["ZX2020005-5"],"award-info":[{"award-number":["ZX2020005-5"]}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-2019Genecast-024"],"award-info":[{"award-number":["Y-2019Genecast-024"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The data for dacomitinib, a second-generation EGFR-TKI, treating patients with advanced non-small cell lung cancer (NSCLC) and brain metastasis was lacking. This study aimed to explore the efficacy and safety of dacomitinib in treating EGFR-mutated advanced NSCLC with brain metastasis in first-line settings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Eligible patients were treatment-na\u00efve advanced NSCLC patients with \u22651 brain metastasis no less than 5\u00a0mm treated with dacomitinib. The primary endpoint was intracranial objective response rate (ORR). Secondary endpoints included intracranial and extracranial progression-free survival (PFS), overall survival (OS), intracranial and extracranial ORR, disease control rate (DCR), and safety. The response was evaluated per modified Response Evaluation Criteria in Solid Tumors (mRECIST) and RANO-BM (Response Assessment in Neuro-Oncology Brain Metastases) criteria.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Result<\/jats:title>\n                  <jats:p>Between July 2nd, 2019, and September 30th, 2022, a total of 87 treatment-na\u00efve patients with advanced NSCLC and brain metastasis treated with dacomitinib from four hospitals were included. The data cutoff date was March 24th, 2023, and the median duration of follow-up time was 17.5 months (range 1.6-34.7 months). Based on mRECIST criteria, for all the 87 patients with evaluable brain metastasis, the iORR was 89.7% (95%CI, 81.3%-95.2%) and iDCR was 97.7% (95%CI, 91.9-99.7%), with 42 patients achieving CR, 36 patients achieving PR, and 7 patients maintaining SD. Based on RANO-BM criteria, the iORR was 71.3% (62\/87, 95%CI 60.6%-80.5%) and iDCR was 97.7% (85\/87, 95%CI, 91.9%-99.7%), with 42 patients achieving CR, 20 patients achieving PR, and 23 patients maintaining SD (Table). Median iPFS was 26.0 (95%CI, 20.7-31.4) months, and the 1-year and 2-year iPFS rate were 68.9% and 51.5%, respectively. Of 75 patients with evaluable extracranial lesions, 2 patients achieved CR (2.7%), the systemic ORR was 73.8% (95%CI 63.1%-82.8%) and DCR was 96.4% (89.9%-99.3%) (Table). Systemic median PFS was 14.0 (95%CI 11.1-16.9) months and median OS was 34.0 (95%CI 28.0-39.9) months. Overall, 86 of 87 (98.9%) patients experienced adverse events (AEs) of any grade. The most common (\u226520%) AEs including rash (89.7%), oral ulcer (74.2%), diarrhea (67.8%), and paronychia (59.8%). Most of the AEs were grade 1 or grade 2 and no patients died due to severe AEs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Dacomitinib showed promising efficacy and a manageable safety profile for advanced NSCLC with brain metastasis harboring EGFR mutation in the first-line treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf079","type":"journal-article","created":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T06:09:04Z","timestamp":1746943744000},"source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of dacomitinib in treatment-na\u00efve patients with advanced NSCLC and brain metastasis: a multicenter cohort study"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4415-9892","authenticated-orcid":false,"given":"Puyuan","family":"Xing","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing , 100021,\u00a0","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxiang","family":"Pu","sequence":"additional","affiliation":[{"name":"The Second Department of Thoracic Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University\/Hunan Cancer Hospital , Changsha, 410013,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[{"name":"The Second Department of Thoracic Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University\/Hunan Cancer Hospital , Changsha, 410013,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziling","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, the First Hospital of Jilin University , Changchun , 130031,\u00a0","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Oncology, the First Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an, 710061,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing , 100021,\u00a0","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouzheng","family":"Wang","sequence":"additional","affiliation":[{"name":"The Department of Oncology, Beijing Chest Hospital , Beijing , 101149,\u00a0","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Hu","sequence":"additional","affiliation":[{"name":"The Department of Oncology, Beijing Chest Hospital , Beijing , 101149,\u00a0","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7361-325X","authenticated-orcid":false,"given":"Junling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing , 100021,\u00a0","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7078-7767","authenticated-orcid":false,"given":"Lin","family":"Wu","sequence":"additional","affiliation":[{"name":"The Second Department of Thoracic Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University\/Hunan Cancer Hospital , Changsha, 410013,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,11]]},"reference":[{"key":"2025051102085541000_CIT0001","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2025051102085541000_CIT0002","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.3390\/cancers13071616","article-title":"The management of brain metastases-systematic review of neurosurgical aspects","volume":"13","author":"Proescholdt","year":"2021","journal-title":"Cancers"},{"key":"2025051102085541000_CIT0003","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1002\/cncr.30000","article-title":"Risk of brain metastases in patients with nonmetastatic lung cancer: analysis of the metropolitan detroit Surveillance, Epidemiology, and End Results (SEER) data","volume":"122","author":"Goncalves","year":"2016","journal-title":"Cancer"},{"key":"2025051102085541000_CIT0004","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ctrv.2017.02.004","article-title":"Management of brain metastasized non-small cell lung cancer (NSCLC) - from local treatment to new systemic therapies","volume":"54","author":"Tsakonas","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"2025051102085541000_CIT0005","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.21037\/jtd.2017.07.57","article-title":"Correlation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancer","volume":"9","author":"Li","year":"2017","journal-title":"J Thorac Dis"},{"key":"2025051102085541000_CIT0006","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"key":"2025051102085541000_CIT0007","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025051102085541000_CIT0008","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40265-020-01441-6","article-title":"Updated overall survival in a randomized study comparing dacomitinib with gefitinib as first-line treatment in patients with advanced non-small-cell lung cancer and EGFR-activating mutations","volume":"81","author":"Mok","year":"2021","journal-title":"Drugs"},{"key":"2025051102085541000_CIT0009","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.neo.2018.02.004","article-title":"A pre-clinical assessment of the pan-ERBB inhibitor dacomitinib in pediatric and adult brain tumors","volume":"20","author":"Endersby","year":"2018","journal-title":"Neoplasia (New York, NY)"},{"key":"2025051102085541000_CIT0010","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/1535-7163.MCT-14-0736","article-title":"Preclinical test of dacomitinib, an irreversible EGFR inhibitor, confirms its effectiveness for glioblastoma","volume":"14","author":"Zahonero","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"2025051102085541000_CIT0011","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1093\/neuonc\/nox105","article-title":"Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification","volume":"19","author":"Sep\u00falveda-S\u00e1nchez","year":"2017","journal-title":"Neuro-Oncology"},{"key":"2025051102085541000_CIT0012","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.2169\/internalmedicine.4449-20","article-title":"Dramatic response of brain metastasis from EGFR-mutation-positive NSCLC to dacomitinib","volume":"59","author":"Kudo","year":"2020","journal-title":"Intern Med"},{"key":"2025051102085541000_CIT0013","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.lungcan.2020.12.008","article-title":"Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: a brief report","volume":"152","author":"Peng","year":"2021","journal-title":"Lung Cancer"},{"key":"2025051102085541000_CIT0014","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1111\/1759-7714.14222","article-title":"Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases","volume":"12","author":"Zhang","year":"2021","journal-title":"Thorac Cancer"},{"key":"2025051102085541000_CIT0015","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025051102085541000_CIT0016","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"key":"2025051102085541000_CIT0017","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol"},{"key":"2025051102085541000_CIT0018","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejca.2021.12.005","article-title":"Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years","volume":"162","author":"Steindl","year":"2022","journal-title":"Eur J Cancer"},{"key":"2025051102085541000_CIT0019","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.lungcan.2013.08.016","article-title":"Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma","volume":"82","author":"Iuchi","year":"2013","journal-title":"Lung Cancer"},{"key":"2025051102085541000_CIT0020","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol"},{"key":"2025051102085541000_CIT0021","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.21037\/tlcr-20-379","article-title":"The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer","volume":"9","author":"Jung","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"2025051102085541000_CIT0022","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/14737140.2018.1409623","article-title":"Response to afatinib in treatment-na\u00efve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases","volume":"18","author":"Li","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"2025051102085541000_CIT0023","doi-asserted-by":"publisher","first-page":"e274","DOI":"10.1016\/j.cllc.2019.02.009","article-title":"Intracranial responses to afatinib at different doses in patients with EGFR-mutated non-small-cell lung carcinoma and brain metastases","volume":"20","author":"Wei","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"2025051102085541000_CIT0024","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","article-title":"Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity","volume":"22","author":"Ballard","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2025051102085541000_CIT0025","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","article-title":"Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs","volume":"27","author":"Colclough","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025051102085541000_CIT0026","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025051102085541000_CIT0027","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1002\/ijc.33904","article-title":"Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR-mutant nonsmall cell lung cancer with brain metastasis","volume":"150","author":"Zhao","year":"2022","journal-title":"Int J Cancer"},{"key":"2025051102085541000_CIT0028","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3390\/cancers15010187","article-title":"Different tyrosine kinase inhibitors used in treating EGFR-mutant pulmonary adenocarcinoma with brain metastasis and intracranial intervention have no impact on clinical outcomes","volume":"15","author":"Kuo","year":"2022","journal-title":"Cancers"},{"key":"2025051102085541000_CIT0029","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"key":"2025051102085541000_CIT0030","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1200\/JCO.21.02641","article-title":"AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations","volume":"40","author":"Lu","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025051102085541000_CIT0031","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","article-title":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","volume":"10","author":"Shi","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2025051102085541000_CIT0032","doi-asserted-by":"publisher","first-page":"l5460","DOI":"10.1136\/bmj.l5460","article-title":"Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis","volume":"367","author":"Zhao","year":"2019","journal-title":"BMJ"},{"key":"2025051102085541000_CIT0033","doi-asserted-by":"publisher","first-page":"103305","DOI":"10.1016\/j.critrevonc.2021.103305","article-title":"Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: a systematic review and network meta-analysis","volume":"160","author":"Zhao","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025051102085541000_CIT0034","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.2217\/fon-2019-0299","article-title":"Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer","volume":"15","author":"Corral","year":"2019","journal-title":"Future Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/5\/oyaf079\/63142056\/oyaf079.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/5\/oyaf079\/63142056\/oyaf079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T06:09:05Z","timestamp":1746943745000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf079\/8128449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf079","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,5]]},"article-number":"oyaf079"}}